A Major Loss for the ADA, A Major Gain for Lilly
This afternoon Lilly (NYSE:LLY) announced that Dr. David Kendall, currently the chief scientific and medical officer of the American Diabetes Association (ADA), has been named distinguished medical fellow for Lilly. According to the Lilly press release; “In his new role, Kendall will serve as a senior medical advisor for Lilly Diabetes in advocacy and clinical science communities and as a representative to the professional medical community. In addition, he will help provide scientific direction for Lilly in diabetes discovery and clinical development. Other key responsibilities will include the support of Lilly’s medical education efforts and diabetes healthcare evaluation programs.”
Although this announcement does not seem to have anything to do with the lawsuit between Lilly and Amylin (NASDAQ:AMLN) it is worth noting that prior to joining the ADA, Dr. Kendall worked at Amylin. Diabetic Investor would note that based on his public comments on the subject, Dr. Kendall is a supporter of GLP-1 therapy and Bydureon. He is also acutely aware that GLP-1’s and DPP-4’s target exactly the same patient. Considering that he will be reporting to Robert Heine, M.D., vice president medical affairs, Lilly Diabetes, it’s just might possible that he would share his thoughts on this subject.
Given his distinguished career and outstanding reputation in the diabetes community, this is a major gain for Lilly and unfortunately a major blow to the ADA. Dr. Kendall should be congratulated for his outstanding work at the ADA as he has been instrumental in helping the ADA formulate a more focused strategy. Let’s hope he’s equally effective getting Lilly to recognize that it’s time to set aside their differences with Amylin and bring Bydureon to market. A strong patient advocate Dr. Kendall understands all too well that patients with diabetes need more, not less, weapons to help them fight their diabetes.